In this scenario, the evaluation of IFN-gamma GEP, PD-L1 expression, tumor HLA expression, and the on-treatment monitoring of ctDNA levels seems to be the most promising to guide escalating or de-escalating strategies permitting a tailored immunotherapy treatment. The gene discussed is IFNG; the disease is neoplasm.